MediMabBio successfully concluded a Series-A fundraising in February 2021, securing 18 million USD. 7 investors have participated, with current investors also contributing. There are 15 employees in Korea and UK office combined with more than 90 percent of them holding master’s and doctoral degrees. Two of their pipelines, MMB101 and MMB102, are projected to initiate preclinical studies by the end of this year, while another pipeline, MMB011, is set to begin at the start of next year.